Potassium Bromide (KBroVet) for Canine Idiopathic Epilepsy: FDA Full Approval, Dosing, and Monitoring

Bottom line

• Potassium bromide (KBroVet, potassium bromide chewable tablets) received FDA full approval on January 21, 2026 for control of seizures in dogs with idiopathic epilepsy — the first fully approved antiseizure pharmaceutical for this indication and the second animal-health product ever to transition from conditional (2021) to full FDA approval. This formalizes bromide's long-established first-line/add-on role in US practice.[1]
• Bromide is an inorganic halide whose antiseizure effect depends on chloride substitution at GABA-A and glycine-receptor chloride channels; it is not metabolized, is renally excreted in competition with dietary chloride, and has a long elimination half-life (~3–4 weeks in dogs) so steady-state is not reached for 2–3 months after any dose change.[2]
• As of July 2026, real-world US primary-care data (Banfield, 853 dogs) place bromide as the fourth most-prescribed first-line antiseizure drug (11.1%), behind phenobarbital, extended-release levetiracetam, and zonisamide.[3]
• The dominant safety and quality-of-care gap is therapeutic drug monitoring (TDM): serum bromide was monitored in only 31.6% of dogs receiving it, versus 77.5% for phenobarbital in the same cohort — a documented practice gap, not a dosing change.[3]
• Bromide's principal long-term risk is bromism (chronic toxicity: sedation, ataxia, hindlimb weakness, confusion, stupor); dietary chloride changes can precipitate toxicity or loss of seizure control, so counsel owners to hold diet constant and monitor serum concentrations on a structured schedule.[2]

Drug facts

• Class: Inorganic halide antiseizure medication; bromide ion.
• Mechanism of action: Chloride-channel stabilization — bromide substitutes for chloride at GABA-A and glycine-receptor-associated chloride channels, enhancing inhibitory neurotransmission and raising the seizure threshold.[2]
• Route / interval: Oral (chewable tablet or liquid). Once- or twice-daily; once-daily predominates in practice (83.3% of bromide-treated dogs in US primary care). Dose is individualized to serum-concentration targeting.[3]
• Typical maintenance dose: ~30 mg/kg/day was the median maintenance dose in US primary care; the label/current formulary governs the final regimen.[3]
• Indication: Control of seizures in dogs with idiopathic epilepsy (KBroVet, FDA full approval January 21, 2026; conditionally approved January 2021).[1]
• Approval status: First FDA-fully-approved pharmaceutical for control of seizures associated with idiopathic epilepsy in dogs; previously used off-label / under compounding in the US; established first-line and add-on role in the veterinary epilepsy canon.[1]
• Label contraindications / cautions: Known bromide hypersensitivity; renal impairment (reduced bromide clearance); caution with hepatic disease. Not recommended in cats (bronchopneumopathy risk; cats are more bromide-sensitive than dogs).[2]
• Common adverse effects: Sedation, ataxia, hindlimb weakness, polydipsia/polyuria/polyphagia, vomiting, and bromism (chronic toxicity syndrome). Pancreatitis has been reported in association with bromide, though causality is debated.[2]

What the evidence shows

Does the FDA full approval change how bromide is used?

The 2026 full approval of KBroVet formalizes a decades-long off-label use pattern rather than altering the pharmacology. It gives clinicians a labeled formulation, a defined dosing framework, and product-specific adverse-event reporting channels.[1] KBroVet is only the second animal-health product across any disease to move from conditional to full FDA approval, and it is the first fully approved pharmaceutical specifically indicated for control of seizures associated with canine idiopathic epilepsy.[1] The practical implication: dosing and monitoring principles that already governed off-label bromide use continue to apply — the approval does not change recommended dosing, which remains a label and current-formulary decision.[3]

How does bromide work, and why is pharmacokinetics clinically load-bearing?

Bromide is the oldest antiseizure medication, with clinical use in human and veterinary medicine dating to the 19th century and more than 30 years of continuous veterinary use.[2] Its antiseizure action relies on substitution for chloride at membrane channels, stabilizing inhibitory neurotransmission. Pharmacokinetically it behaves as an inorganic ion: distributed throughout total body water with a large volume of distribution, not metabolized, and excreted renally in direct competition with dietary chloride.[2]

That chloride competition is the crux of safe use. Diets high in chloride (e.g., increased sodium chloride intake) accelerate bromide renal clearance, lowering serum levels and risking loss of seizure control; low-chloride diets slow excretion, raising levels and bromism risk. Combined with a ~3–4 week elimination half-life, steady-state is not reached until roughly 2–3 months after initiating or changing a dose, so serum monitoring must be timed to this kinetics. Counsel owners to hold the diet formulation constant throughout therapy and to notify the practice before any dietary change.[2]

How commonly is bromide actually prescribed in US primary care?

Pompermaier and colleagues (2026) retrospectively reviewed Banfield Pet Hospital electronic medical records (January 2020–December 2023), identifying 853 dogs meeting strict criteria for idiopathic epilepsy.[3] First-line antiseizure prescribing was:

• Phenobarbital — 34.9% (most prescribed)
• Levetiracetam (extended-release) — 31.3%
• Zonisamide — 22.9%
• Potassium bromide — 11.1%

For bromide specifically, the median maintenance dose was ~30 mg/kg/day, administered once daily in 83.3% of dogs. Prescribing patterns generally aligned with ACVIM guidance. The narrative review by Gouveia et al. (2024) frames bromide's modern role consistently: most often an alternative or add-on antiseizure medication rather than a default first choice — used as an add-on when phenobarbital or levetiracetam alone does not achieve control, and as a first-line agent where phenobarbital is relatively contraindicated (e.g., concurrent hepatic disease).[2]

The therapeutic drug monitoring gap (contested priority, hard data)

The signal that most distinguishes real-world practice from guideline intent is monitoring. In the same 853-dog cohort, serum bromide was monitored in only 31.6% of dogs receiving it, versus 77.5% monitoring for phenobarbital.[3] The authors flag this variability and the need for both updated dosing evidence and clinician education on the value of monitoring.

Why the gap matters clinically: bromide's long half-life and narrow-ish therapeutic window make serum concentration central to distinguishing a genuine breakthrough seizure from a subtherapeutic concentration or early bromism — a distinction that changes the next therapeutic step.[2][3] The neutral synthesis across both sources: the data put a real-world denominator on a long-suspected practice gap and support prioritizing serum checks for bromide with the same rigor already applied to phenobarbital, without implying any change to recommended dosing.[3]

Adverse-effect profile and bromism

The Gouveia et al. (2024) review is the most current clinician-focused synthesis of bromide's adverse-effect profile.[2] It characterizes bromism (chronic bromide toxicity) as the principal safety concern of long-term use, presenting as progressive neurological signs — sedation, ataxia, hindlimb weakness, confusion, and, in severe cases, stupor. Additional effects include polydipsia, polyuria, polyphagia, and gastrointestinal signs such as vomiting. Bromide's adverse effects are noted to affect both patients and owners (e.g., polyuria/polydipsia burden), a factor in shared decision-making.

Pancreatitis has been reported in association with bromide use, but the causal relationship remains debated in the literature — present it to owners as an association to watch for, not an established causal risk.[2] Cats are more sensitive to bromide adverse effects than dogs and bromide is not recommended in cats owing to bronchopneumopathy risk.[2]

Where bromide sits in the broader antiseizure hierarchy

The 2024 ACVIM Consensus Statement on management of status epilepticus and cluster seizures in dogs and cats provides the surrounding context.[4] Although that consensus focuses on acute/emergency management, it reinforces the evidence base supporting established maintenance antiseizure medications — including bromide — as part of chronic background therapy alongside phenobarbital and levetiracetam.

Contraindications, precautions & PK

• Contraindicated / use with caution: known bromide hypersensitivity; renal impairment (reduced clearance drives accumulation and bromism); caution with hepatic disease. Avoid in cats (bronchopneumopathy; greater bromide sensitivity).[2]
• Pharmacokinetics that dictate monitoring: not metabolized; renal excretion in competition with dietary chloride; large volume of distribution across total body water; half-life ~3–4 weeks, so steady-state at ~2–3 months after any dose change. Time serum sampling to steady-state, not to the next visit of convenience.[2]
• Diet–drug interaction: any change in dietary chloride shifts serum bromide — high chloride lowers it (risk: breakthrough seizures), low chloride raises it (risk: bromism). Hold diet constant; re-check levels after unavoidable diet changes.[2]
• Adverse-effect triggers for reassessment: new or worsening sedation, ataxia, hindlimb weakness, or confusion warrant immediate serum bromide measurement to rule out bromism.[2]

Practical decision support

• When to reach for bromide: as an add-on when phenobarbital and/or levetiracetam do not achieve control, or first-line where phenobarbital is relatively contraindicated (e.g., hepatic disease).[2]
• Set owner expectations up front: the ~3-month timeline to steady-state, the requirement for consistent diet, the clinical signs of bromism that require immediate reassessment, and the need for scheduled serum monitoring.[2]
• Close the TDM gap: treat serum bromide monitoring as non-optional and give it the same priority phenobarbital already receives — the 31.6% vs 77.5% real-world gap is a direct, actionable target for workflow improvement and patient safety.[3]
• Interpreting breakthrough seizures: before escalating dose, check whether a "breakthrough" reflects a subtherapeutic serum concentration (or a recent diet change) rather than true refractoriness.[2][3]
• Dosing remains a label/formulary decision: the evidence above documents prescribing and monitoring patterns and pharmacology; it does not redefine target doses.[3]

Frequently Asked Questions

Is potassium bromide FDA approved for dogs? Yes. On January 21, 2026 the FDA granted full approval to KBroVet (potassium bromide chewable tablets) for control of seizures in dogs with idiopathic epilepsy — the first fully approved pharmaceutical for this indication, following conditional approval in 2021.[1]

How often should serum bromide be monitored, and how often is it actually done? Monitoring is central to safe use because of bromide's long half-life and narrow-ish therapeutic window. In a large US primary-care cohort, serum bromide was monitored in only 31.6% of treated dogs versus 77.5% for phenobarbital — a documented practice gap. Time sampling to steady-state (~2–3 months after a dose change).[2][3]

Why does diet affect bromide levels? Bromide is excreted renally in competition with dietary chloride. High-chloride diets accelerate bromide clearance (lowering levels and risking breakthrough seizures); low-chloride diets slow clearance (raising levels and bromism risk). Keep the diet constant and re-check levels after any change.[2]

How commonly is bromide used as a first-line antiseizure drug in US primary care? It was the fourth most-prescribed first-line agent (11.1% of 853 dogs), behind phenobarbital (34.9%), extended-release levetiracetam (31.3%), and zonisamide (22.9%).[3]

What is bromism and how does it present? Bromism is chronic bromide toxicity — progressive neurological signs including sedation, ataxia, hindlimb weakness, confusion, and, in severe cases, stupor. New or worsening signs warrant immediate serum bromide measurement.[2]

Can bromide be used in cats? No — bromide is not recommended in cats due to bronchopneumopathy risk, and cats are more sensitive to its adverse effects than dogs.[2]

Does the 2026 primary-care data change recommended bromide dosing? No. It documents a therapeutic-drug-monitoring gap, not a dosing change. Dosing remains a label and current-formulary decision; the takeaway is to prioritize serum monitoring when bromide is used.[3]

How long until bromide reaches steady-state after a dose change? Roughly 2–3 months, because bromide's elimination half-life in dogs is approximately 3–4 weeks. Serum monitoring should be timed accordingly rather than checked prematurely.[2]

Changelog

• 2026-06-09: First published.
• 2026-07-06: Consolidated the June 16, 2026 dispatch on the bromide-vs-phenobarbital TDM gap into this evergreen hub; expanded the monitoring, decision-support, and FAQ sections with the 31.6% vs 77.5% real-world denominators (no new studies — the dispatch's citations were already covered by references 2 and 3). Corrected the FDA approval date to January 21, 2026 and set the primary animal to dog.